Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial
ACR Open Rheumatol. 2023;5(1):38–48 doi: 10.1002/acr2.11511
Results of a phase II trial of evobrutinib suggest that Bruton's Tyrosine Kinase (BTK) inhibition is not an efficacious therapeutic intervention over standard of care therapy for patients with SLE.
Following the development of BTK inhibitors for a range of autoimmune diseases, and the potential role of BTK in the pathogenesis of SLE, Wallace, et al. sought to determine the efficacy and safety of evobrutinib in patients with autoantibody-positive SLE and active disease receiving standard of care therapy. Although generally well-tolerated, evobrutinib failed to show a treatment effect versus placebo.